SOLANA BEACH, Calif., April 07, 2026 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (Nasdaq: ARTL), a scientific‑level pharmaceutical corporate taken with modulating lipid‑signaling pathways to expand remedies for other folks residing with most cancers, ache, dermatological, or neurological prerequisites, these days introduced that it has won a letter from The Nasdaq Inventory Marketplace LLC (“Nasdaq”) confirming that the Corporate has regained compliance with Nasdaq Record Rule 5550(b)(1), the “Equity Rule,” and Record Rule 5620(a), the “Annual Shareholders Meeting Rule.”
Nasdaq additional showed that, in keeping with the Corporate’s Shape 8-Ok filed January 30, 2026, the Corporate held its reconvened annual assembly on that date and, in keeping with the Corporate’s Shape 8-Ok filed March 30, 2026, the Corporate regained compliance with the Fairness Rule. Based on Nasdaq Record Rule 5815(d)(4)(B), the Corporate shall be matter to a compulsory panel track for a duration of 1 12 months from the date of the letter.
“We are pleased to have regained compliance with Nasdaq’s continued listing requirements,” stated Gregory D. Gorgas, President and Leader Govt Officer of Artelo Biosciences. “With this matter behind us, we remain focused on disciplined execution across our portfolio, including progressing potential partnership negotiations with ART27.13 boosted by the encouraging Phase 2 CAReS interim data suggesting its potential for mitigating or reversing the effects of cancer anorexia-cachexia syndrome.”
ART27.13 may be beneath investigation in an externally funded Section 2 find out about as an orally administered agent for the remedy of glaucoma. Artelo’s 2d scientific level investigational drug and the primary product candidate derived from our FABP5 inhibitor platform, ART26.12 is advancing as a non-opioid and non-scheduled drug for the remedy of neuropathic ache.
“As we continue to advance our pipeline with a focus on high-value indications and capital-efficient development, we believe Artelo is well-positioned to unlock meaningful long-term value for shareholders,” added Gorgas
About Artelo Biosciences
Ahead Taking a look Statements
This press unlock incorporates sure forward-looking statements throughout the which means of Segment 27A of the Securities Act of 1933 and Segment 21E of the Securities Alternate Act of 1934, as amended, together with statements in regards to the Corporate’s plans and expectancies. Those statements contain identified and unknown dangers, uncertainties, and different components that can purpose exact effects to range materially from the ones expressed or implied by way of such statements, together with marketplace and different prerequisites. All statements that don’t seem to be ancient information are forward-looking statements, together with however now not restricted to, statements referring to: the usage of proceeds from the providing and the possible workout of the warrants. For a dialogue of dangers and uncertainties, please consult with the Corporate’s filings with the Securities and Alternate Fee, together with its most up-to-date Annual Record on Shape 10-Ok. The Corporate undertakes no legal responsibility to publicly replace any forward-looking remark, with the exception of as required by way of appropriate securities regulations.
